EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of clarithromycin in the management of pediatric leprosy cases: an economic evaluation

Kelli Carneiro de Freitas Nakata, Ternize Mariana Guenkka, Priscilla Perez da Silva Pereira, Alytissa Kalyne da Silva Cosme, Gilson Yugi Nakata, Zenóbia Quinderé Barreto, Lucí Emilia Grzybowski de Oliveira, Letícia Rossetto da Silva Cavalcante

HTA Journal · 09.10.2026

DOI: 10.67516/htaj.26.3.99 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HTA Journal, online erschienen am 09.10.2026. Verfasst von Kelli Carneiro de Freitas Nakata und 7 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Leprosy remains a major public health challenge in hyperendemic regions, and new pediatric cases signal recent, active transmission. Children who require substitution of a multidrug therapy (MDT) component because of adverse events, rifampicin resistance, or glucose-6-phosphate dehydrogenase (G6PD) deficiency currently lack approved second-line therapeutic options.

Objective

To conduct an economic evaluation analyzing costs and estimating the budget impact of incorporating clarithromycin oral suspension as a second-line therapeutic alternative for pediatric leprosy cases requiring MDT substitution in a Brazilian state. Methodology: A cost-minimization analysis and a budget impact analysis were conducted from the perspective of the Brazilian Unified Health System (SUS), using a decision-tree model with a 12-month and a five-year time horizon, respectively. The target population was children aged 6 months to 12 years. Parameters were based on local epidemiological data, public procurement prices, and expert consensus obtained through the Delphi technique. A univariate deterministic sensitivity analysis tested the robustness of the model.

Results

Incorporating clarithromycin resulted in an average incremental cost of US$ 185.27 per case per year. The annual budget impact was estimated at US$ 38,353.44, with a cumulative five-year impact of US$ 191,767.21. The sensitivity analysis showed that the annual budget impact could range from US$ 30,682.75 to US$ 107,880.94, depending on fluctuations in the drug price.

Conclusions

The incorporation of clarithromycin oral suspension 50 mg/mL is recommended as a second-line option for pediatric leprosy cases requiring MDT substitution in the analyzed state. To standardize access and promote the rational use of the medication, a clinical protocol should accompany its incorporation.

Zitieren

APA

Nakata, K. C. D. F., Guenkka, T. M., Pereira, P. P. D. S., Cosme, A. K. D. S., Nakata, G. Y., Barreto, Z. Q., Oliveira, L. E. G. D., & Cavalcante, L. R. D. S. (2026). Use of clarithromycin in the management of pediatric leprosy cases: an economic evaluation. HTA Journal. https://doi.org/10.67516/htaj.26.3.99

Vancouver

Nakata KCDF, Guenkka TM, Pereira PPDS, Cosme AKDS, Nakata GY, Barreto ZQ, et al. Use of clarithromycin in the management of pediatric leprosy cases: an economic evaluation. HTA Journal. 2026. doi:10.67516/htaj.26.3.99

BibTeX
@article{Nakata2026,
  author = {Nakata, Kelli Carneiro de Freitas and Guenkka, Ternize Mariana and Pereira, Priscilla Perez da Silva and Cosme, Alytissa Kalyne da Silva and Nakata, Gilson Yugi and Barreto, Zenóbia Quinderé and Oliveira, Lucí Emilia Grzybowski de and Cavalcante, Letícia Rossetto da Silva},
  title = {Use of clarithromycin in the management of pediatric leprosy cases: an economic evaluation},
  journal = {HTA Journal},
  year = {2026},
  doi = {10.67516/htaj.26.3.99}
}
Kostenlos starten →